DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03923114

iPAVE

CompletedPhase NA

Imaging Pituitary ActiVation by Exendin

iPAVE - Imaging Pituitary ActiVation by Exendin

Assets

Exenatide / GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Pituitary uptake of Ga-68-NODAGA-exendin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03923114
Org study IDNL67316.091.18

Timeline

Milestones

Study first posted2019-04-22actual
Study start2019-05-23actual
Primary completion2024-04-03actual
Study completion2024-04-03actual
Last update posted2024-05-22actual

Assets

Investigational agents

ExenatideGLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Patients with treatment response:

•Age ≥18 years
•Subject is diagnosed with type 2 diabetes
•Subject showed response to GLP-1RA treatment
•Ability to sign informed consent

Patients without treatment response:

•Age ≥18 years
•Subject is diagnosed with type 2 diabetes
•Subject showed no response to GLP-1RA treatment
•Ability to sign informed consent

Exclusion criteria

•Liver disease
•Renal disease
•Pregnancy or the wish to become pregnant within 6 months after the study
•Breastfeeding
•Age <18 years
•Pituitary disorder
•Inability to sign informed consent
•Exclusion criteria for MR:
–Fragments, clips or devices in brain, eyes, spinal canal
–Implantable defibrillator or pacemaker (wires)
–Mandibular magnetic implants
–Neurostimulator, bladder stimulator, non-removable insulin pump
–Metal tissue-expander in chest
–Cochlear implant
–Ossicular replacement prosthesis

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Metabolic status (OGTT)

Time frame:1.5 year

descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Pituitary uptake of Ga-68-NODAGA-exendin

Time frame:1.5 year

descriptive

Secondary/protocol endpoint/low confidence

Metabolic status (ACTH)

Time frame:1.5 year

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.